United Therapeutics Corporation
UTHR
Clasificación en acciones
#998
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Precio por acción
$551.89
Última sincronización: 2026-10-20
Capitalización bursátil
$23.67B
Cambio (1 día)
1.61%
Cambio (1 año)
30.61%
País
US
Comercio United Therapeutics Corporation (UTHR)
Categoría
Healthcare
Ingresos de United Therapeutics Corporation (UTHR)
Ingresos en Jun 2026 TTM: $3.15B
Según los últimos informes financieros de United Therapeutics Corporation, los ingresos actuales de la empresa (TTM) son $3.15B. En 2023, la empresa obtuvo unos ingresos de $2.33B un aumento con respecto a los ingresos del año 2022, que fueron de $1.94B. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de United Therapeutics Corporation desde 2000 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $3.15B | 9.63% |
| 2024 | $2.88B | 23.63% |
| 2023 | $2.33B | 20.20% |
| 2022 | $1.94B | 14.88% |
| 2021 | $1.69B | 13.63% |
| 2020 | $1.48B | 2.38% |
| 2019 | $1.45B | -11.00% |
| 2018 | $1.63B | -5.65% |
| 2017 | $1.73B | 7.91% |
| 2016 | $1.60B | 9.08% |
| 2015 | $1.47B | 13.76% |
| 2014 | $1.29B | 15.36% |
| 2013 | $1.12B | 21.93% |
| 2012 | $916.08M | 23.26% |
| 2011 | $743.18M | 23.08% |
| 2010 | $603.83M | 63.26% |
| 2009 | $369.85M | 31.39% |
| 2008 | $281.50M | 33.45% |
| 2007 | $210.94M | 32.14% |
| 2006 | $159.63M | 37.71% |
| 2005 | $115.92M | 57.51% |
| 2004 | $73.59M | 37.96% |
| 2003 | $53.34M | 77.09% |
| 2002 | $30.12M | 425.50% |
| 2001 | $5.73M | 179.70% |
| 2000 | $2.05M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 300.20% |
US
|
|
| $2.23B | -29.37% |
US
|
|
| $15.74B | 399.11% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 90.88% |
NL
|
